We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00196352
First Posted: September 20, 2005
Last Update Posted: April 8, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Teva Pharmaceutical Industries
  Purpose
This study is being conducted to evaluate the safety of ethinyl an extended-regimen oral contraceptive, with ethinyl estradiol supplementation during the usual hormone-free week, for up to an additional three consecutive years.

Condition Intervention Phase
Contraception Drug: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Prospective, Multiple Site Study to Evaluate the Safety of an Extended Cycle Combination Oral Contraceptive, Seasonique, Which Utilizes Ethinyl Estradiol During the Pill-free Interval.

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Patient and Investigator reports of adverse events [ Time Frame: Duration of Study ]

Enrollment: 320
Study Start Date: May 2003
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets
1 tablet daily
Other Name: Seasonique

Detailed Description:
This study is being conducted to evaluate the safety of an extended-regimen oral contraceptive, with ethinyl estradiol supplementation during the usual hormone-free week, for up to an additional three consecutive years. This is an extension of the Seasonique Phase 3 clinical trial to evaluate long-term safety. Only patients enrolled in the earlier trial are eligible for participation.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participant in the earlier Phase 3 Seasonique clinical trial

Exclusion Criteria:

  • Any contraindication to the use of oral contraceptives
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00196352


Locations
United States, Arizona
Duramed Investigational Site
Tucson, Arizona, United States, 85715
United States, District of Columbia
Duramed Investigational Site
Washington, District of Columbia, United States, 20006
United States, Nebraska
Duramed Investigational Site
Lincoln, Nebraska, United States, 68510
United States, New York
Duramed Investigational Site
Rochester, New York, United States, 14609
United States, North Carolina
Duramed Investigational Site
Charlotte, North Carolina, United States, 28209
Duramed Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Duramed Investigational Site
Columbus, Ohio, United States, 43213
United States, Oklahoma
Duramed Investigational Site
Oklahoma City, Oklahoma, United States, 73112
United States, Tennessee
Duramed Investigational Site
Nashville, Tennessee, United States, 37203
United States, Virginia
Duramed Investigational Site
Arlington, Virginia, United States, 22203
Duramed Investigational Site
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Duramed Research
Investigators
Study Chair: Duramed Protocol Chair Duramed Research, Inc.
  More Information

Responsible Party: Duramed Protocol Chair, Duramed Research, Inc.
ClinicalTrials.gov Identifier: NCT00196352     History of Changes
Other Study ID Numbers: PSE-304
First Submitted: September 12, 2005
First Posted: September 20, 2005
Last Update Posted: April 8, 2014
Last Verified: April 2014

Keywords provided by Teva Pharmaceutical Industries:
oral contraceptives
birth control
ethinyl estradiol
pregnancy prevention

Additional relevant MeSH terms:
Estradiol
Ethinyl Estradiol
Contraceptive Agents
Levonorgestrel
Ethinyl estradiol, levonorgestrel drug combination
Contraceptives, Oral
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral, Combined